Preliminary study of selective estrogen modulators (SERMs) combined with maximum androgen blockade for metastatic prostate cancer
Not Applicable
- Conditions
- Bone metastatic prostate cancer
- Registration Number
- JPRN-UMIN000006400
- Lead Sponsor
- the University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Liver dysfunction, thrombosis, using bisphosphonate, warfarin, phenobarbital, rifampicin, or ampicillin. Urinary tract infection, mental disease, the patients decided not applicable for this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA-relapse-free survival
- Secondary Outcome Measures
Name Time Method VAS, and QO